Physician profile
Emily Key
NPI 1821525593
$1,138.27
in general payments reported to CMS, 2019-2025
11 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $226 · 2022: $30.54 · 2023: $470 · 2024: $100 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $882.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $881.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $386.44 | 2023-2025 | |
| Abbott Laboratories | $166.09 | 2021 | |
| Glaxosmithkline, LLC. | $162.12 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $118.40 | 2023-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $88.08 | 2022-2023 | Mounjaro |
| Astrazeneca Pharmaceuticals LP | $61.92 | 2022-2025 | Farxiga, Breztri |
| Collegium Pharmaceutical, INC. | $44.91 | 2021 | |
| Exact Sciences Corporation | $41.40 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $40.47 | 2025 | Caplyta |
| Horizon Therapeutics Plc | $14.78 | 2021 | |
| Currax Pharmaceuticals LLC | $13.66 | 2023 | Contrave, Onzetra Xsail |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Key listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.